Access
To read this story in full you will need to login or make a payment (see right).
insight
Nature 415, 716 (7 February 2002) | doi:10.1038/415716a
corporate support GlaxoSmithKline & malaria
Malaria is a public health problem in more than 90 countries and 40% of the global population is vulnerable to this potentially deadly disease. Around one million children die from malaria each year in Africa alone and resistance to the most commonly used and affordable anti-malarial drugs is developing rapidly.
To read this story in full you will need to login or make a payment (see right).